Skip to main content

Donor/Recipient Insurance Coverage: Protecting Against Unexpected Liability

  • Chapter
  • First Online:
  • 1081 Accesses

Abstract

Oocyte donation (OD) was originally intended for reproductive-aged women with premature ovarian failure and women with intractable infertility. However, currently OD serves the reproductive needs of a more diverse group of women, including women of advanced maternal age and postmenopausal patients. Despite oocyte donation being an expensive procedure, its popularity can be attributed to its high rate of success. Oocyte donation is now more commonly performed than ever. Yet, inherent risks to both the donor and recipient still exist. Measures to protect all parties, including the IVF practices that offer such services, from potential expenses secondary to complications must be established to maintain a viable and operationally sound program.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Sauer MV, Kavic SM. Oocyte and embryo donation 2006: reviewing two decades of innovation and controversy. Reprod Biomed Online. 2006;12:153–62.

    Article  PubMed  Google Scholar 

  2. Buster JE, Bustillo M, Thorneycroft IH, Simon JA, Boyers SP, Marshall JR, et al. Non-surgical transfer of in vivo fertilised donated ova to five infertile women: report of two pregnancies. Lancet. 1983;2:223–4.

    Article  PubMed  CAS  Google Scholar 

  3. Trounson A, Leeton J, Besanko M, Wood C, Conti A. Pregnancy established in an infertile patient after transfer of a donated embryo fertilised in vitro. Br Med J (Clin Res Ed). 1983;286:835–8.

    Article  CAS  Google Scholar 

  4. Klein J, Sauer MV. Oocyte donation. Best Pract Res Clin Obstet Gynaecol. 2002;16:277–91.

    Article  PubMed  Google Scholar 

  5. Thinking of Becoming an Egg Donor. New York State Task Force on Life and the Law – Advisory Group on Assisted Reproductive Technologies. http://www.health.ny.gov/publications/1127.pdf.

  6. Sauer MV, Paulson RJ, Lobo RA. Rare occurrence of ovarian hyperstimulation syndrome in oocyte donors. Int J Gynaecol Obstet. 1996;52:259–62.

    Article  PubMed  CAS  Google Scholar 

  7. Sauer MV. Defining the incidence of serious complications experienced by oocyte donors: a review of 1000 cases. Am J Obstet Gynecol. 2001;184:277–8.

    Article  PubMed  CAS  Google Scholar 

  8. Bukulmez O, Li Q, Carr BR, Leader B, Doody KM, Doody KJ. Repetitive oocyte donation does not decrease serum anti-Mullerian hormone levels. Fertil Steril. 2010;94:905–12.

    Article  PubMed  CAS  Google Scholar 

  9. Gelbaya TA. Short and long-term risks to women who conceive through in vitro fertilization. Hum Fertil (Camb). 2010;13:19–27.

    Article  Google Scholar 

  10. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril. 2004;82:405–14.

    Article  PubMed  Google Scholar 

  11. Konishi I, Kuroda H, Mandai M. Review: gonadotropins and development of ovarian cancer. Oncology. 1999;57 Suppl 2:45–8.

    Article  PubMed  CAS  Google Scholar 

  12. Practice Committee of American Society for Reproductive Medicine; Practice Committee of Society for Assisted Reproductive Technology. 2008 guidelines for gamete and embryo donation: a Practice Committee report. Fertil Steril. 2008;90:S30–44.

    Google Scholar 

  13. Jain T, Harlow BL, Hornstein MD. Insurance coverage and outcomes of in vitro fertilization. N Engl J Med. 2002;347:661–6.

    Article  PubMed  Google Scholar 

  14. Egg Donor/Recipient Insurance. 2011. ART Risk Insurance and Financial Solution, Inc. http://www.artrisksolutions.com/eggDonorSurIP.php.

  15. Fertility Insurance Program. 2012. Brown & Brown, Inc. https://www.bbinsurance.com.

  16. Reproductive Technology Risk Solutions. 2012. Beitler Services, Inc. http://www.beitlerservies.com.

  17. IVF Insurance Payment Program Plan. 2003-2012. © New Life Agency, Insurance Agency, Inc. http://www.newlifeagency.com.

  18. Accident and Health Insurance. 2012. © 2012 American International Group, Inc. http://www.­aigcorporate.com.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Cary Lisa Dicken M.D. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Dicken, C.L. (2013). Donor/Recipient Insurance Coverage: Protecting Against Unexpected Liability. In: Sauer, M. (eds) Principles of Oocyte and Embryo Donation. Springer, London. https://doi.org/10.1007/978-1-4471-2392-7_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2392-7_19

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2391-0

  • Online ISBN: 978-1-4471-2392-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics